News
Shares in Novo Nordisk fell as much as 6% on Friday to their lowest since August 2021, extending recent losses to wipe out ...
Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...
1h
Free Malaysia Today on MSNNovo Nordisk’s shares extend losses, erasing nearly all gains since Wegovy launchNovo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions ...
Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss. Together, these blockbuster drugs made Novo the most valuable publicly ...
Medical bottles and a syringe are seen with the Novo Nordisk logo displayed on a screen in the background.
Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results